Using Real-World Data for Drug Repurposing and Pharmacovigilance
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1725
Special Issue Editors
Interests: observational health data research; health data governance; distributed analysis; federated learning; AI for healthcare
Interests: health insurance database research; medical informatics; medical ethics; ophthalmology; neuro-ophthalmology
Interests: clinical data analysis; precision medicine; biotech and healthcare management
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Drug repurposing is the process of identifying new uses for existing drugs or compounds. Pharmacovigilance is the study of the safety of drugs and their potential side effects. Real-world data can be used for both purposes. There are several sources of real-world data, including electronic health records, claims data, and patient registry data. These data sources can provide information about how drugs are being used in real-world clinical practice, as well as any adverse events or side effects that may be associated with their use. Examples, such as research of how statins could be protective for cancer development other than the initial intention of being protective for cardiovascular diseases, or hydroxycholoroquine in the treatment of autoimmune disease, such as rheumatoid arthritis, could lead to maculopathy, which could cast an impact on quality of life for poor vision. Nowadays, many drugs are being developed, such as monoclonal antibodies, to tackle cancers and autoimmune diseases, which will make this kind of study more imperative and insightful, as we are all learning from the real-world evidence.
By combining real-world data and omics data (i.e., genomics, metabolomics, proteomics, microbiomics, etc.) from biobanks, researchers can gain a more comprehensive understanding of the molecular mechanisms and improve the accuracy and precision of their scientific findings.
Dr. Min-Huei Hsu
Dr. Ju-Chuan Yen
Dr. Jason C. Hsu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- real-world data
- observational study
- drug repurposing
- pharmacovigilance
- electronic health record
- omics
- biobank
